Guide to Lipoprotein (a)

WRITTEN BY
Updated: 05/22/2025|12 min read

Summary

Lipoprotein(a), or Lp(a), is a specific form of cholesterol particle in your blood that behaves differently in your body than regular LDL, potentially increasing your risk for heart disease and stroke.

Why It Matters

Lp(a) contributes to heart disease and stroke risk in several ways that are different from regular cholesterol:

First, Lp(a) is "stickier" than other types of LDL cholesterol. This makes it more likely to form blood clots, attach to the walls of your arteries, and contribute to plaque buildup.

LEVELS APP + LABS

See how the Levels Heart Health program helps you act on your Lp(a).

  • Focus on adjacent modifiable markers like ApoB, LDL, and triglycerides
  • Follow app-guided targets for fiber, saturated fat, and net carbs
  • Retest Lp(a) and related markers in a Comprehensive panel
Take the 60-second plan quiz

Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.

Upload your labs free

Free lab interpretation

Already have labs?

Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.

Upload your labs free

Second, Lp(a) promotes inflammation in blood vessels, which can damage arterial walls and accelerate plaque formation.

Third, Lp(a) interferes with your body's natural ability to dissolve blood clots. This means clots can form more easily and are harder to break down, increasing the risk of heart attacks and strokes.

What makes Lp(a) testing particularly important is that your levels are primarily determined by genetics rather than lifestyle factors. Unlike other cholesterol measurements, Lp(a) seems resistant to most diet and exercise interventions. Around 20-30% of people have genetically elevated levels.

Research shows that people with high Lp(a) have a 2-3 times higher risk of heart attack and CVD and an increased risk of stroke compared to those with lower levels, regardless of their other risk factors. Because Lp(a) levels typically remain stable throughout your life, a single test can provide valuable information about this specific risk factor.

Understanding your Lp(a) status is valuable because:

  1. If your level is elevated, your doctor may recommend more aggressive management of other risk factors you can control (like blood pressure or LDL cholesterol)
  2. Knowing you have elevated Lp(a) may lower the threshold for starting preventive medications
  3. Family members may benefit from testing, as high levels run in families
  4. You may qualify for clinical trials of new treatments that specifically target Lp(a)

Associated Symptoms

Lipoprotein(a) levels themselves are laboratory findings rather than medical conditions. However, elevated levels may be associated with various cardiovascular conditions, each with their own symptoms.

Common symptoms that may indicate conditions associated with elevated Lp(a):

  • Chest discomfort: Pain, pressure, or tightness in the chest (angina) can result from reduced blood flow to the heart muscle
  • Dyspnea: Shortness of breath during physical activity can be due to compromised cardiovascular function
  • Fatigue: Persistent tiredness can result from decreased oxygen delivery to tissues due to atherosclerotic narrowing
  • Extremity symptoms: Pain, numbness, or weakness in the legs may result from peripheral artery disease, causing reduced blood flow
  • Neurological symptoms: Sudden numbness, weakness, speech difficulties, vision problems, or headache, indicating possible stroke from Lp(a)-related blood clots

It's important to understand that elevated Lp(a) itself typically causes no direct symptoms. The symptoms listed above generally appear only after significant cardiovascular disease has developed, which may take years or decades. This is why testing for Lp(a) is valuable for risk assessment before symptoms occur.

Low Lp(a) levels may be associated with malnutrition, alcoholism, and chronic hepatocellular disease.

Clinical Ranges

Lab Reference Range: < 75 nmol/L

Lifestyle Factors That Can Impact It

Activities that may help manage cardiovascular risk with elevated Lp(a) include the following:

  • Regular physical activity
  • A diet rich in fruits, vegetables, and healthy fats
  • A healthy weight
  • Stress management

Activities that may worsen cardiovascular risk with elevated Lp(a) include the following:

  • Smoking (compounds risk)
  • A high saturated fat diet
  • Sedentary lifestyle
  • Uncontrolled diabetes
  • Uncontrolled hypertension

Other Factors That Can Impact It

Important Context: While Lp(a) levels are approximately 70-90% determined by genetics, certain conditions and medications can cause modest changes in your levels. These factors typically don't transform very low levels into high-risk ones (or vice versa), but they may be relevant in people with borderline levels or when monitoring the effectiveness of treatments.

The changes described below are generally modest compared to the genetic influence. For instance, even significant lifestyle changes might only affect Lp(a) levels by 10-15%, while the difference between genetically "low" and "high" Lp(a) people can be 1,000-fold or more. However, understanding these factors can help contextualize your test results and inform your overall cardiovascular risk management strategy.

Medical Conditions

  • Chronic kidney disease: Increases Lp(a) levels in certain people due to lowered clearance from the bloodstream
  • Hypothyroidism: Increases Lp(a) levels through altered liver metabolism of lipoproteins
  • Type 2 diabetes: Potentially increases levels through glycation of lipoproteins, which may enhance negative cardiovascular effects
  • Postmenopause: Increases levels likely due to reduced estrogen production
  • Autoimmune disorders such as rheumatoid arthritis and lupus: Increase Lp(a) levels through inflammation

Medications and Supplements

  • High-dose niacin (500 mg daily): Reduces Lp(a) levels by decreasing liver production of apolipoprotein(a)
  • CoQ10: Has been shown to have a modest lowering effect on Lp(a)
  • Hormone Replacement therapy (specifically estrogen) may lower Lp(a)
  • Neomycin may lower Lp(a)
  • PCSK9 inhibitors (evolocumab, alirocumab): Reduce Lp(a) by reducing production and increasing clearance through enhanced LDL receptor activity
  • Hormone replacement therapy: In postmenopausal women, can lower Lp(a) by reducing production in the liver
  • Statins: May slightly increase levels in some patients
  • Emerging antisense oligonucleotide therapies (pelacarsen): Reduce Lp(a) by targeting production
  • Regular aspirin use: May help counteract some of Lp(a)'s prothrombotic effects

Testing Accuracy and Stability

Lp(a) is relatively stable. Compared to other lipids, it has low biological variability, with day-to-day variability around  10-20 percent. That said, a few factors can impact results.

Factors That Can Affect the Accuracy of Your Test

  • Acute illness or inflammation can temporarily raise results.
  • Pregnancy can cause temporary increases in levels.

How it Relates to Other Markers

Lp(a) is an independent risk factor for cardiovascular disease. But it should be interpreted alongside other cardiovascular markers, such as:

  • Total cholesterol and LDL: Elevated Lp(a) compounds the risk associated with high LDL.
  • Triglycerides: High Lp(a) and high triglycerides together increase cardiovascular risk.
  • C-reactive protein (CRP): Elevated Lp(a) and CRP may suggest both genetic and inflammatory contributors to cardiovascular risk.
  • Homocysteine: The combination of high Lp(a) and high homocysteine significantly increases thrombotic risk.

What Results May Mean in the Context of Other Markers

  • High Lp(a) with high LDL: Can indicate substantially increased cardiovascular risk; aggressive LDL reduction is typically recommended.
  • High Lp(a) with normal LDL: May still indicate elevated cardiovascular risk; Lp(a) contributes to risk independent of LDL levels.
  • High Lp(a) with low HDL: Can be a particularly concerning combination as both are independent risk factors; doctors may recommend raising HDL through exercise and dietary changes may be beneficial.
  • High Lp(a) with high triglycerides: May suggests multiple pathways of cardiovascular risk; management of metabolic health is especially important.
  • High Lp(a) with elevated inflammatory markers: Can suggests compounded risk through multiple mechanisms; anti-inflammatory strategies may be particularly important.
  • Normal Lp(a) with elevated LDL and triglycerides: Traditional lipid-lowering approaches can be effective; Lp(a) may not add additional risk in this scenario.
  • High Lp(a) with other normal lipid parameters: May still represent elevated cardiovascular risk; don't dismiss the risk despite an otherwise "normal" cholesterol profile.

Follow-up Considerations

If your Lp(a) levels are high, your healthcare provider may help you take steps to address the issue, including lifestyle changes, retesting, and additional tests. You should always speak to your doctor if you have medical questions or before making medical decisions.

When Re-Testing May be Appropriate

  • Normal levels: Testing once in adulthood is usually sufficient.
  • Elevated levels: Repeat testing is generally unnecessary as levels remain stable.
  • During clinical trials or specific treatments targeting Lp(a): Retest as directed by a healthcare provider.

Additional Testing Your Doctor May Consider

  • Comprehensive lipid panel
  • Advanced lipoprotein testing
  • Cardiovascular imaging in high-risk people
  • Family screening for elevated Lp(a)

When Additional Care May be Warranted

  • Personal history of premature cardiovascular disease
  • Family history of premature cardiovascular disease with elevated Lp(a)
  • Recurrent cardiovascular events despite optimal LDL control
  • Multiple cardiovascular risk factors in addition to elevated Lp(a)

Bibliography

References

1. Tsimikas, Sotirios. "A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies." Journal of the American College of Cardiology, vol. 69, no. 6, 2017, pp. 692--711. https://doi.org/10.1016/j.jacc.2016.11.042.

2. Wilson, Don P., et al. "Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. A Scientific Statement from the National Lipid Association." Journal of Clinical Lipidology, vol. 13, no. 3, 2019, pp. 374--392. https://doi.org/10.1016/j.jacl.2019.04.010.

3. Berglund, Lars, et al. "Lipoprotein(a): An Elusive Cardiovascular Risk Factor." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, 2004, pp. 2219--2226. https://doi.org/10.1373/clinchem.2013.210070.

4. Nordestgaard, Børge G., et al. "Lipoprotein(a) as a Cardiovascular Risk Factor: Current Status." European Heart Journal, vol. 31, no. 23, 2010, pp. 2844--2853. https://doi.org/10.1093/eurheartj/ehq386.

5. Boffa, Michael B., et al. "Lipoprotein(a) as a Risk Factor for Atherosclerosis and Thrombosis: Mechanistic Insights from Animal Models." Clinical Biochemistry, vol. 37, no. 5, 2004, pp. 333--343. https://doi.org/10.1016/j.clinbiochem.2004.02.007.

6. Clarke, Robert, et al. "Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease." New England Journal of Medicine, vol. 361, no. 26, 2009, pp. 2518--2528. https://doi.org/10.1056/NEJMoa0902604.

7. Kamstrup, Pia R., et al. "Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction." JAMA, vol. 301, no. 22, 2009, pp. 2331--2339. https://doi.org/10.1001/jama.2009.801.

8. Emerging Risk Factors Collaboration, Erqou, Sebhat, et al. "Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality." JAMA, vol. 302, no. 4, 2009, pp. 412--423. https://doi.org/10.1001/jama.2009.1063.

9. Laffin, Luke J., and Steven E. Nissen. "Lp(a) -- An Overlooked Risk Factor." Trends in Cardiovascular Medicine, vol. 34, no. 3, 2024, pp. 193--199.

10. Enas, Enas A., et al. "Lipoprotein(a): An Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction." Indian Heart Journal, vol. 71, no. 2, 2019, pp. 99--112. https://doi.org/10.1016/j.ihj.2019.03.001.

11. Broncel, Marlena. "Why and When Should Lipoprotein(a) Level Be Measured?" Exploratory Cardiology, vol. 1, 2023, pp. 180--192.

12. Saeedi, Ramin, and John Frohlich. "Lipoprotein (a), an Independent Cardiovascular Risk Marker." Clinical Diabetes and Endocrinology, vol. 2, 2016, article 7. https://doi.org/10.1186/s40842-016-0022-2.

13. Clair, V., et al. "Rethinking Cardiovascular Risk: The Emerging Role of Lipoprotein(a) Screening." American Journal of Preventive Cardiology, vol. 21, 2025, article 100945. https://doi.org/10.1016/j.ajpc.2025.100945.

14. Langsted, Anne, et al. "Low Lipoprotein(a) Levels and Risk of Disease in a Large, Contemporary, General Population Study." European Heart Journal, vol. 42, no. 12, 2021, pp. 1147--1156. https://doi.org/10.1093/eurheartj/ehaa936.

15. Najjar, Rami S., et al. "Consumption of a Defined, Plant-Based Diet Reduces Lipoprotein(a), Inflammation, and Other Atherogenic Lipoproteins and Particles Within 4 Weeks." Clinical Cardiology, vol. 41, no. 8, 2018, pp. 1062--1068. https://doi.org/10.1002/clc.23024.

16. Reyes-Soffer, Gabrielle, et al. "Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 42, no. 1, 2022, pp. e48--e60. https://doi.org/10.1161/ATV.0000000000000145.

17. Hopewell, J. C., et al. "The Role of Lipoprotein (a) in Chronic Kidney Disease." Journal of Lipid Research, vol. 59, no. 4, 2018, pp. 577--585. https://doi.org/10.1194/jlr.R082149.

18. Brenta, Gabriela, et al. "Lipoprotein Alterations, Hepatic Lipase Activity, and Insulin Sensitivity in Subclinical Hypothyroidism." Thyroid, vol. 17, no. 5, 2007, pp. 453--460. https://doi.org/10.1089/thy.2006.0256.

19. Lamina, Cornelia, and Natalie C. Ward. "Lipoprotein (a) and Diabetes Mellitus." Atherosclerosis, vol. 349, 2022, pp. 63--71. https://doi.org/10.1016/j.atherosclerosis.2022.03.016.

20. Arnold, A. "Primary Hyperparathyroidism: Molecular Genetic Insights and Clinical Implications." Endocrine Abstracts, vol. 50, 2017, abstract PL1.

21. Connolly, Caitlin M., et al. "Lipoprotein(a) in Systemic Lupus Erythematosus is Associated with History of Proteinuria and Reduced Renal Function." Lupus, vol. 31, no. 11, 2022, pp. 1367--1372. https://doi.org/10.1177/09612033221121512.

22. Artemeva, N. V., et al. "Lowering of Lipoprotein(a) Level Under Niacin Treatment is Dependent on Apolipoprotein(a) Phenotype." Atherosclerosis Supplements, vol. 18, 2015, pp. 53--58. https://doi.org/10.1016/j.atherosclerosissup.2015.02.009.

23. Boffa, Michael B., and Marlys L. Koschinsky. "Therapeutic Lowering of Lipoprotein(a): A Role for Pharmacogenetics?" Circulation: Genomic and Precision Medicine, vol. 11, no. 2, 2018, article e002052. https://doi.org/10.1161/CIRCGEN.117.002052.

24. O'Donoghue, Michelle L., et al. "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk." Circulation, vol. 139, no. 12, 2019, pp. 1483--1492. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.

25. Safarova, Maya S., and Iftikhar J. Kullo. "Lipoprotein(a) Lowering and Cardiovascular Risk Reduction by PCSK9 Inhibitors." Atherosclerosis, vol. 361, 2022, pp. 30--31. https://doi.org/10.1016/j.atherosclerosis.2022.03.010.

26. Raal, Frederick J., et al. "PCSK9 Inhibition-Mediated Reduction in Lp(a) with Evolocumab: An Analysis of 10 Clinical Trials." Journal of Lipid Research, vol. 57, no. 6, 2016, pp. 1086--1096. https://doi.org/10.1194/jlr.M064915.

27. de Boer, Lotte M., et al. "Statin Therapy and Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis." European Journal of Preventive Cardiology, vol. 29, no. 5, 2022, pp. 779--792. https://doi.org/10.1093/eurjpc/zwab189.

28. Yeang, Chen, et al. "Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol." Journal of the American College of Cardiology, vol. 79, no. 11, 2022, pp. 1035--1046. https://doi.org/10.1016/j.jacc.2022.01.034.

29. Fernandez-Prado, Ruben, et al. "Pelacarsen for Lowering Lipoprotein(a): Implications for Patients with Chronic Kidney Disease." Clinical Kidney Journal, vol. 13, no. 5, 2020, pp. 753--757. https://doi.org/10.1093/ckj/sfz190.

30. Al Hageh, Christelle, et al. "Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions." Vascular Health and Risk Management, vol. 19, 2023, pp. 31--41. https://doi.org/10.2147/VHRM.S390792.

31. Assmann, Günther, et al. "Hypertriglyceridemia and Elevated Lipoprotein(a) Are Risk Factors for Major Coronary Events in Middle-Aged Men." American Journal of Cardiology, vol. 77, no. 14, 1996, pp. 1179--1184. https://doi.org/10.1016/S0002-9149(97)89134-2.

32. Zhang, Wei, et al. "High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis." Journal of the American College of Cardiology, vol. 78, no. 11, 2021, pp. 1083--1094. https://doi.org/10.1016/j.jacc.2021.07.002.

33. D'Angelo, Anthony, and Jacob Selhub. "Homocysteine and Thrombotic Disease." Blood, vol. 90, no. 1, 1997, pp. 1--11. https://doi.org/10.1182/blood.V90.1.1.1.

34. Feng, Zhu, et al. "Elevated Homocysteine Intensifies the Effect of Lipoprotein(a) on Stroke Recurrence." Journal of the American Heart Association, vol. 12, no. 1, 2023, article e026707. https://doi.org/10.1161/JAHA.122.026707.

35. Zhu, Lin, et al. "The Correlation Between Lipoprotein(a) Elevations and the Risk of Recurrent Cardiovascular Events in CAD Patients with Different LDL-C Levels." BMC Cardiovascular Disorders, vol. 22, 2022, article 171. https://doi.org/10.1186/s12872-022-02638-1.

36. Bhatia, H. S., et al. "Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis." Circulation, vol. 151, no. 4, 2025, pp. 312--321. https://doi.org/10.1161/CIRCULATIONAHA.124.XXXXXXX (DOI placeholder if not published yet)

37. von Eckardstein, Arnold, et al. "Lipoprotein(a) Further Increases the Risk of Coronary Events in Men with High Global Cardiovascular Risk." Journal of the American College of Cardiology, vol. 37, no. 2, 2001, pp. 434--439. https://doi.org/10.1016/S0735-1097(00)01121-7.

38. Marco-Benedí, Victoria, et al. "Influence of Triglyceride Concentration in Lipoprotein (a) as a Function of Dyslipidemia." Clinica e Investigación en Arteriosclerosis, vol. 36, no. 2, 2024, pp. 71--77. https://doi.org/10.1016/j.arteri.2023.06.004.

39. Di Fusco, Salvatore A., et al. "Lipoprotein (a), Inflammation, and Atherosclerosis." Journal of Clinical Medicine, vol. 12, no. 7, 2023, article 2529. https://doi.org/10.3390/jcm12072529.

LEVELS APP + LABS

See how the Levels Heart Health program helps you act on your Lp(a).

  • Focus on adjacent modifiable markers like ApoB, LDL, and triglycerides
  • Follow app-guided targets for fiber, saturated fat, and net carbs
  • Retest Lp(a) and related markers in a Comprehensive panel
Take the 60-second plan quiz

Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.

Upload your labs free
LEVELSAI

Ask a question about this topic

Get instant answers to your health and nutrition questions with an AI Search powered by the full Levels blog.

Try LevelsAI
Sign up for the Levels Newsletter